Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price fell 0.8% during mid-day trading on Friday . The company traded as low as $26.07 and last traded at $26.14. 7,442,691 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 42,334,875 shares. The stock had previously closed at $26.34.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on PFE. UBS Group lowered their target price on shares of Pfizer from $34.00 to $27.00 and set a "neutral" rating on the stock in a research note on Thursday, December 14th. Truist Financial reduced their price target on shares of Pfizer from $42.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, December 14th. Barclays reduced their price target on shares of Pfizer from $34.00 to $28.00 and set an "equal weight" rating for the company in a report on Thursday, December 14th. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Finally, TD Cowen downgraded shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $36.88.
View Our Latest Stock Analysis on PFE
Pfizer Stock Down 1.8 %
The firm has a market cap of $146.49 billion, a price-to-earnings ratio of 71.86, a PEG ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The business's 50-day moving average is $27.28 and its 200-day moving average is $28.93.
Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm's revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter last year, the company posted $1.14 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.
Institutional Investors Weigh In On Pfizer
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RB Capital Management LLC grew its position in shares of Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock worth $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. lifted its stake in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank lifted its stake in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock valued at $2,416,000 after buying an additional 290 shares in the last quarter. Ergoteles LLC lifted its stake in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock valued at $1,903,000 after buying an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its stake in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock valued at $69,238,000 after buying an additional 79,887 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
